West Pharmaceutical Services Company Profile (NYSE:WST)

About West Pharmaceutical Services (NYSE:WST)

West Pharmaceutical Services logoWest Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company's products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. The Company's segments include Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment develops commercial and operational strategies across its global network, with specific emphasis on product offerings to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as an integrated business focused on the design, manufacture and automated assembly of various devices, primarily for pharmaceutical, diagnostic and medical device customers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Symbol: NYSE:WST
  • CUSIP: 95530610
  • Web: www.westpharma.com
Capitalization:
  • Market Cap: $7.01 billion
  • Outstanding Shares: 73,553,000
Average Prices:
  • 50 Day Moving Avg: $88.01
  • 200 Day Moving Avg: $84.23
  • 52 Week Range: $70.17 - $96.97
P/E:
  • Trailing P/E Ratio: 39.45
  • Foreward P/E Ratio: 31.66
  • P/E Growth: 1.83
Sales & Book Value:
  • Annual Revenue: $1.53 billion
  • Price / Sales: 4.58
  • Book Value: $15.89 per share
  • Price / Book: 6.00
Dividend:
  • Annual Dividend: $0.52
  • Dividend Yield: 0.6%
Profitability:
  • EBIDTA: $324.3 million
  • Net Margins: 9.27%
  • Return on Equity: 14.54%
  • Return on Assets: 9.30%
Debt:
  • Debt-to-Equity Ratio: 0.20%
  • Current Ratio: 2.78%
  • Quick Ratio: 1.93%
Misc:
  • Average Volume: 373,237 shs.
  • Beta: 0.94
  • Short Ratio: 3.5
 

Frequently Asked Questions for West Pharmaceutical Services (NYSE:WST)

What is West Pharmaceutical Services' stock symbol?

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

How often does West Pharmaceutical Services pay dividends? What is the dividend yield for West Pharmaceutical Services?

West Pharmaceutical Services declared a quarterly dividend on Tuesday, May 16th. Stockholders of record on Wednesday, July 19th will be given a dividend of $0.13 per share on Wednesday, August 2nd. This represents a $0.52 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend is Monday, July 17th. View West Pharmaceutical Services' Dividend History.

How were West Pharmaceutical Services' earnings last quarter?

West Pharmaceutical Services Inc. (NYSE:WST) announced its quarterly earnings results on Thursday, April, 27th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.55 by $0.26. The firm earned $387.70 million during the quarter, compared to the consensus estimate of $380.42 million. West Pharmaceutical Services had a return on equity of 14.54% and a net margin of 9.27%. The business's revenue was up 7.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.53 earnings per share. View West Pharmaceutical Services' Earnings History.

When will West Pharmaceutical Services make its next earnings announcement?

West Pharmaceutical Services is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for West Pharmaceutical Services.

What guidance has West Pharmaceutical Services issued on next quarter's earnings?

West Pharmaceutical Services updated its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of $2.45-2.57 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.51. The company issued revenue guidance of $1.585-1.610 billion, compared to the consensus revenue estimate of $1.60 billion.

Where is West Pharmaceutical Services' stock going? Where will West Pharmaceutical Services' stock price be in 2017?

3 brokers have issued 1 year price objectives for West Pharmaceutical Services' shares. Their predictions range from $72.55 to $90.00. On average, they anticipate West Pharmaceutical Services' share price to reach $81.28 in the next twelve months. View Analyst Ratings for West Pharmaceutical Services.

What are analysts saying about West Pharmaceutical Services stock?

Here are some recent quotes from research analysts about West Pharmaceutical Services stock:

  • 1. According to Zacks Investment Research, "West Pharmaceutical Services applies technologies to the process of bringing new drug therapies and healthcare products. West's technologies include the design and manufacture of packaging components for pharmaceutical, healthcare and consumer products; research and development of drug delivery systems; contract manufacturing and packaging services; clinical services; and contract laboratory services and other services that support the manufacturing, filling and packaging of pharmaceutical, healthcare and consumer products. " (4/29/2017)
  • 2. Jefferies Group LLC analysts commented, "WST's formal '17 guidance featured a 1% higher CC revenue growth (7-9% from 6-8%) and continued margin expansion driven by high-value product growth. But that wasn't enough. At 33x '17, we thought the market discounted inflecting EPS growth, which has made valuation look stretched to us. FX headwinds ($35-45M; $0.05-0.07) and slightly rising tax rate negate the faster top-line. Maintain Hold." (2/21/2017)

Who are some of West Pharmaceutical Services' key competitors?

Who owns West Pharmaceutical Services stock?

West Pharmaceutical Services' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.79%), BlackRock Inc. (7.92%), Neuberger Berman Group LLC (5.40%), State Street Corp (3.32%), JPMorgan Chase & Co. (2.77%) and Eagle Asset Management Inc. (1.82%). Company insiders that own West Pharmaceutical Services stock include Daniel Malone, Heino Lennartz, John E Paproski, Karen Flynn, Michael A Anderson, Patrick J Zenner, Paula A Johnson, Thomas W Hofmann, Warwick Bedwell and William J Federici. View Institutional Ownership Trends for West Pharmaceutical Services.

Who sold West Pharmaceutical Services stock? Who is selling West Pharmaceutical Services stock?

West Pharmaceutical Services' stock was sold by a variety of institutional investors in the last quarter, including Kalmar Investments Inc. DE, Granahan Investment Management Inc. MA, OppenheimerFunds Inc., IronBridge Capital Management LP, State Street Corp, Nationwide Fund Advisors, Bank of America Corp DE and TIAA CREF Investment Management LLC. Company insiders that have sold West Pharmaceutical Services stock in the last year include Daniel Malone, Karen Flynn, Paula A Johnson, Thomas W Hofmann and William J Federici. View Insider Buying and Selling for West Pharmaceutical Services.

Who bought West Pharmaceutical Services stock? Who is buying West Pharmaceutical Services stock?

West Pharmaceutical Services' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Wells Fargo & Company MN, JPMorgan Chase & Co., Morgan Stanley, First Trust Advisors LP, FMR LLC and MARSHALL WACE ASIA Ltd. View Insider Buying and Selling for West Pharmaceutical Services.

How do I buy West Pharmaceutical Services stock?

Shares of West Pharmaceutical Services can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of West Pharmaceutical Services stock cost?

One share of West Pharmaceutical Services stock can currently be purchased for approximately $95.30.

Analyst Ratings

Consensus Ratings for West Pharmaceutical Services (NYSE:WST) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $81.28 (14.72% downside)

Analysts' Ratings History for West Pharmaceutical Services (NYSE:WST)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/28/2017Jefferies Group LLCReiterated RatingHold$82.00 -> $90.00LowView Rating Details
12/23/2016Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
10/28/2016Wells Fargo & CoUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for West Pharmaceutical Services (NYSE:WST)
Earnings by Quarter for West Pharmaceutical Services (NYSE:WST)
Earnings History by Quarter for West Pharmaceutical Services (NYSE:WST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017        
4/27/2017Q1 2017$0.55$0.81$380.42 million$387.70 millionViewN/AView Earnings Details
2/16/2017Q416$0.56$0.54$387.31 million$382.30 millionViewListenView Earnings Details
10/27/2016Q316$0.53$0.53$371.76 million$376.70 millionViewListenView Earnings Details
7/28/2016Q216$0.56$0.59$384.58 million$388.00 millionViewListenView Earnings Details
4/28/2016Q116$0.51$0.53$355.86 million$362.10 millionViewListenView Earnings Details
2/18/2016Q415$0.47$0.47$364.76 million$359.70 millionViewListenView Earnings Details
10/29/2015Q315$0.43$0.44$355.90 million$344.50 millionViewListenView Earnings Details
7/30/2015Q215$0.45$0.47$356.33 million$359.70 millionViewListenView Earnings Details
4/30/2015Q115$0.40$0.45$346.64 million$335.90 millionViewListenView Earnings Details
2/19/2015Q414$0.46$0.45$348.33 million$349.80 millionViewListenView Earnings Details
10/30/2014Q314$0.43$0.44$356.08 million$355.90 millionViewListenView Earnings Details
7/31/2014Q214$0.47$0.52$368.60 million$368.90 millionViewN/AView Earnings Details
5/1/2014Q114$0.41$0.38$340.90 million$346.80 millionViewListenView Earnings Details
2/20/2014Q413$0.38$0.38$348.70 million$342.70 millionViewListenView Earnings Details
10/31/2013Q3 13$0.36$0.39$333.25 million$341.80 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.82$0.86$349.85 million$344.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.86$0.87$344.20 million$339.40 millionViewListenView Earnings Details
2/21/2013Q4 2012$0.56$0.61$318.75 million$321.50 millionViewListenView Earnings Details
11/1/2012Q312$0.50$0.52$306.91 million$303.80 millionViewN/AView Earnings Details
8/2/2012$0.69$0.79ViewN/AView Earnings Details
4/26/2012$0.65$0.83ViewN/AView Earnings Details
2/16/2012$0.55$0.59ViewN/AView Earnings Details
11/1/2011$0.54$0.53ViewN/AView Earnings Details
7/28/2011$0.68$0.62ViewN/AView Earnings Details
4/28/2011$0.62$0.60ViewN/AView Earnings Details
2/17/2011$0.46$0.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for West Pharmaceutical Services (NYSE:WST)
2017 EPS Consensus Estimate: $2.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.55$0.55$0.55
Q2 20171$0.59$0.59$0.59
Q3 20171$0.68$0.68$0.68
Q4 20171$0.70$0.70$0.70
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for West Pharmaceutical Services (NYSE:WST)
Next Dividend:8/2/2017
Annual Dividend:$0.52
Dividend Yield:0.55%
Dividend Growth:8.40% (3 Year Average)
Payout Ratio:28.11% (Trailing 12 Months of Earnings)
19.05% (Based on This Year's Estimates)
17.28% (Based on Next Year's Estimates)
Track Record:24 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for West Pharmaceutical Services (NYSE:WST)

Dividend History by Quarter for West Pharmaceutical Services (NYSE:WST)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/16/2017quarterly$0.130.54%7/17/20177/19/20178/2/2017
2/16/2017Quarterly$0.134/17/20174/19/20175/3/2017
12/14/2016quarterly$0.130.61%1/13/20171/18/20172/1/2017
9/12/2016quarterly$0.1310/17/201610/19/201611/2/2016
7/6/2016Quarterly$0.127/18/20167/20/20168/3/2016
3/4/2016Quarterly$0.124/18/20164/20/20165/4/2016
12/17/2015Quarterly$0.121/15/20161/20/20162/3/2016
7/15/2015quarterly$0.120.79%10/19/201510/21/201511/4/2015
7/2/2015quarterly$0.110.76%7/20/20157/22/20158/5/2015
2/20/2015quarterly$0.110.82%4/20/20154/22/20155/6/2015
12/22/2014quarterly$0.110.81%1/16/20151/21/20152/4/2015
7/16/2014quarterly$0.1110/20/201410/22/201411/5/2014
7/16/2014quarterly$0.111.11%10/15/201410/19/201411/3/2014
5/8/2014quarterly$0.100.94%7/21/20147/23/20148/6/2014
2/20/2014quarterly$0.100.83%4/21/20144/23/20145/7/2014
12/19/2013quarterly$0.100.81%1/17/20141/22/20142/5/2014
8/1/2013quarterly$0.2010/23/201311/6/2013
5/10/2013quarterly$0.191.16%7/22/20137/24/20138/7/2013
3/15/2013quarterly$0.191.21%4/15/20134/17/20135/1/2013
12/27/2012quarterly$0.191.4%1/18/20131/23/20132/6/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for West Pharmaceutical Services (NYSE:WST)
Insider Ownership Percentage: 5.13%
Institutional Ownership Percentage: 90.31%
Insider Trades by Quarter for West Pharmaceutical Services (NYSE:WST)
Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)
Insider Trades by Quarter for West Pharmaceutical Services (NYSE:WST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017William J. FedericiCFOSell54,996$95.45$5,249,368.20View SEC Filing  
5/2/2017Daniel MaloneVPSell4,124$93.31$384,810.44View SEC Filing  
12/8/2016Patrick J. ZennerDirectorBuy332$84.53$28,063.96View SEC Filing  
10/31/2016Paula A. JohnsonDirectorSell2,466$75.87$187,095.42View SEC Filing  
9/6/2016Karen FlynnSVPSell14,581$83.28$1,214,305.68View SEC Filing  
8/23/2016Paula A JohnsonDirectorSell3,042$81.55$248,075.10View SEC Filing  
6/2/2016Daniel MaloneVPSell3,950$74.95$296,052.50View SEC Filing  
5/25/2016Thomas W HofmannDirectorSell2,466$73.57$181,423.62View SEC Filing  
3/1/2016Michael A AndersonVPSell16,414$63.58$1,043,602.12View SEC Filing  
2/29/2016Thomas W HofmannDirectorSell3,042$62.70$190,733.40View SEC Filing  
2/25/2016Heino LennartzInsiderSell5,680$62.47$354,829.60View SEC Filing  
2/24/2016Heino LennartzInsiderSell19,658$59.45$1,168,668.10View SEC Filing  
2/23/2016Paula A. JohnsonDirectorSell7,800$59.39$463,242.00View SEC Filing  
2/22/2016Warwick BedwellInsiderSell16,042$59.52$954,819.84View SEC Filing  
11/25/2015John E. PaproskiinsiderSell17,560$63.41$1,113,479.60View SEC Filing  
11/12/2015Heino LennartzInsiderSell3,500$61.87$216,545.00View SEC Filing  
11/6/2015Michael A AndersonVPSell3,000$62.18$186,540.00View SEC Filing  
11/5/2015Michael A. AndersonVPSell10,000$61.98$619,800.00View SEC Filing  
11/4/2015Daniel MaloneVPSell4,456$61.65$274,712.40View SEC Filing  
8/17/2015William J FedericiCFOSell52,678$59.72$3,145,930.16View SEC Filing  
5/28/2015Heino LennartzInsiderSell9,584$55.00$527,120.00View SEC Filing  
5/22/2015Karen FlynnInsiderSell3,091$55.24$170,746.84View SEC Filing  
5/21/2015Eric Mark GreenCEOBuy18,300$54.89$1,004,487.00View SEC Filing  
5/18/2015Karen FlynnInsiderSell1,909$55.00$104,995.00View SEC Filing  
5/15/2015Donald E Morel JrCEOSell20,000$54.29$1,085,800.00View SEC Filing  
2/27/2015Richard D LuzziVPSell10,000$54.85$548,500.00View SEC Filing  
2/26/2015Michael A AndersonVPSell4,682$54.93$257,182.26View SEC Filing  
2/25/2015Heino LennartzInsiderSell3,617$54.82$198,283.94View SEC Filing  
2/24/2015John E PaproskiInsiderSell9,282$52.87$490,739.34View SEC Filing  
2/23/2015Heino LennartzInsiderSell21,040$53.40$1,123,536.00View SEC Filing  
2/23/2015Patrick J ZennerDirectorSell12,800$53.69$687,232.00View SEC Filing  
11/26/2014Richard D LuzziVPSell8,000$52.11$416,880.00View SEC Filing  
11/21/2014William J FedericiCFOSell3,000$51.22$153,660.00View SEC Filing  
11/20/2014Donald E Morel JrCEOSell20,000$51.30$1,026,000.00View SEC Filing  
11/13/2014John R GaileyVPSell28,000$52.37$1,466,360.00View SEC Filing  
11/11/2014Michael A AndersonVPSell4,600$51.73$237,958.00View SEC Filing  
11/10/2014Warwick BedwellInsiderSell6,306$49.95$314,984.70View SEC Filing  
8/21/2014Richard D LuzziVPSell10,000$44.07$440,700.00View SEC Filing  
8/20/2014John R GaileyVPSell20,000$43.96$879,200.00View SEC Filing  
8/19/2014Michael A AndersonVPSell9,800$43.41$425,418.00View SEC Filing  
8/18/2014William J FedericiCFOSell38,366$42.56$1,632,856.96View SEC Filing  
8/13/2014Heino LennartzInsiderSell7,555$39.65$299,555.75View SEC Filing  
8/11/2014Heino LennartzInsiderSell11,445$40.00$457,800.00View SEC Filing  
8/7/2014John E PaproskiInsiderSell14,000$40.44$566,160.00View SEC Filing  
5/30/2014Richard D LuzziVPSell22,828$42.17$962,656.76View SEC Filing  
5/29/2014Heino LennartzInsiderSell2,000$43.00$86,000.00View SEC Filing  
2/28/2014Heino LennartzInsiderSell16,044$45.84$735,456.96View SEC Filing  
2/26/2014Patrick J ZennerDirectorSell12,800$46.12$590,336.00View SEC Filing  
2/24/2014Warwick BedwellInsiderSell24,606$47.49$1,168,538.94View SEC Filing  
11/26/2013Donald E Morel JrCEOSell35,000$48.60$1,701,000.00View SEC Filing  
11/22/2013William J FedericiCFOSell36,000$48.34$1,740,240.00View SEC Filing  
11/19/2013Karen FlynnInsiderSell5,500$47.75$262,625.00View SEC Filing  
11/8/2013Michael A AndersonVPSell9,200$46.80$430,560.00View SEC Filing  
11/7/2013Heino LennartzInsiderSell5,102$46.70$238,263.40View SEC Filing  
11/6/2013Michael A AndersonVPSell6,000$46.53$279,180.00View SEC Filing  
11/5/2013John R GaileyVPSell6,000$46.83$280,980.00View SEC Filing  
11/5/2013Warwick BedwellInsiderSell6,304$46.84$295,279.36View SEC Filing  
11/4/2013Richard D LuzziVPSell38,708$46.99$1,818,888.92View SEC Filing  
8/30/2013Donald E Morel JrCEOSell10,000$74.46$744,600.00View SEC Filing  
8/27/2013John R GaileyVPSell13,749$76.77$1,055,510.73View SEC Filing  
8/22/2013L Robert JohnsonDirectorSell1,883$76.81$144,633.23View SEC Filing  
8/14/2013John E PaproskiInsiderSell6,011$79.08$475,349.88View SEC Filing  
8/12/2013Anthony WeltersDirectorSell19,200$78.43$1,505,856.00View SEC Filing  
8/8/2013Michael A AndersonVPSell4,300$78.00$335,400.00View SEC Filing  
5/31/2013Michael A AndersonVPSell4,000$68.94$275,760.00View SEC Filing  
5/28/2013Donald E Morel JrCEOSell10,000$67.87$678,700.00View SEC Filing  
5/24/2013L Robert JohnsonDirectorSell1,700$67.47$114,699.00View SEC Filing  
5/20/2013John R GaileyVPSell9,282$68.54$636,188.28View SEC Filing  
5/17/2013L Robert JohnsonDirectorSell4,000$67.80$271,200.00View SEC Filing  
5/8/2013L Robert JohnsonDirectorSell6,400$64.49$412,736.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for West Pharmaceutical Services (NYSE:WST)
Latest Headlines for West Pharmaceutical Services (NYSE:WST)
Source:
DateHeadline
americanbankingnews.com logoWilliam J. Federici Sells 54,996 Shares of West Pharmaceutical Services Inc. (WST) Stock
www.americanbankingnews.com - May 18 at 7:26 PM
prnewswire.com logoWest Announces Quarterly Dividend and Participation in Upcoming Investor ...
www.prnewswire.com - May 17 at 8:12 AM
americanbankingnews.com logo Brokerages Set $98.33 Price Target for West Pharmaceutical Services Inc. (WST)
www.americanbankingnews.com - May 16 at 8:34 PM
americanbankingnews.com logoWest Pharmaceutical Services Inc. Declares Quarterly Dividend of $0.13 (WST)
www.americanbankingnews.com - May 16 at 6:14 PM
finance.yahoo.com logoWest Announces Quarterly Dividend and Participation in Upcoming Investor Conferences
finance.yahoo.com - May 15 at 7:49 PM
finance.yahoo.com logoETFs with exposure to West Pharmaceutical Services, Inc. : May 9, 2017
finance.yahoo.com - May 9 at 8:13 PM
finance.yahoo.com logoWest Pharmaceutical Services, Inc. :WST-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017
finance.yahoo.com - May 8 at 8:14 PM
americanbankingnews.com logo Analysts Anticipate West Pharmaceutical Services Inc. (WST) Will Post Quarterly Sales of $405.33 Million
www.americanbankingnews.com - May 7 at 8:36 AM
americanbankingnews.com logoZacks: Brokerages Expect West Pharmaceutical Services Inc. (WST) Will Announce Earnings of $0.65 Per Share
www.americanbankingnews.com - May 5 at 9:19 AM
americanbankingnews.com logoWest Pharmaceutical Services (WST) Getting Somewhat Favorable Press Coverage, Report Shows
www.americanbankingnews.com - May 3 at 4:30 PM
finance.yahoo.com logoWest Highlights Company Scientific and Regulatory Expertise at Notable Industry Meetings
finance.yahoo.com - May 3 at 9:40 AM
americanbankingnews.com logoWest Pharmaceutical Services Inc. (WST) VP Daniel Malone Sells 4,124 Shares
www.americanbankingnews.com - May 2 at 6:48 PM
americanbankingnews.com logoPositive News Coverage Unlikely to Impact West Pharmaceutical Services (WST) Stock Price
www.americanbankingnews.com - April 30 at 8:46 AM
finance.yahoo.com logoEdited Transcript of WST earnings conference call or presentation 27-Apr-17 1:00pm GMT
finance.yahoo.com - April 30 at 2:21 AM
americanbankingnews.com logoWest Pharmaceutical Services Inc. (WST) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - April 29 at 4:27 PM
americanbankingnews.com logoWest Pharmaceutical Services Inc. (WST) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - April 29 at 7:30 AM
finance.yahoo.com logoWest Pharmaceutical Services, Inc.: Price momentum supported by strong fundamentals
finance.yahoo.com - April 29 at 2:36 AM
finance.yahoo.com logoWhy West Pharmaceutical Services Is Rising Today
finance.yahoo.com - April 28 at 2:12 AM
americanbankingnews.com logoWest Pharmaceutical Services Inc. (WST) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - April 27 at 4:52 PM
nasdaq.com logoWest Pharmaceutical Services (WST) Has Surged To A New High On Q1 News
www.nasdaq.com - April 27 at 11:37 AM
seekingalpha.com logoWest Pharmaceutical Services Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - April 27 at 11:37 AM
finance.yahoo.com logoWest Announces First-Quarter 2017 Results
finance.yahoo.com - April 27 at 11:37 AM
finance.yahoo.com logoWest Pharmaceutical tops Street 1Q forecasts
finance.yahoo.com - April 27 at 11:37 AM
americanbankingnews.com logoWest Pharmaceutical Services (WST) Given Daily Media Impact Score of 0.35
www.americanbankingnews.com - April 27 at 11:10 AM
americanbankingnews.com logoWest Pharmaceutical Services Inc. (WST) Releases FY17 Earnings Guidance
www.americanbankingnews.com - April 27 at 11:00 AM
nasdaq.com logoMedical Product Stocks' Earnings on Apr 27: ZBH, RMD & More
www.nasdaq.com - April 26 at 10:18 PM
finance.yahoo.com logoMedical Product Stocks' Earnings on Apr 27: ZBH, RMD & More
finance.yahoo.com - April 26 at 5:18 PM
americanbankingnews.com logoWest Pharmaceutical Services (WST) Getting Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 24 at 9:54 AM
americanbankingnews.com logoWest Pharmaceutical Services Inc. (WST) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 22 at 10:57 AM
americanbankingnews.com logoWest Pharmaceutical Services (WST) Given Daily Media Sentiment Rating of 0.10
www.americanbankingnews.com - April 21 at 2:49 PM
finance.yahoo.com logoWest Pharmaceutical Services, Inc. : WST-US: Dividend Analysis : April 19th, 2017 (record date) : By the numbers : April 19, 2017
finance.yahoo.com - April 20 at 1:24 AM
americanbankingnews.com logo West Pharmaceutical Services Inc. (WST) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 19 at 9:02 AM
americanbankingnews.com logoWest Pharmaceutical Services (WST) Receiving Very Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 18 at 10:27 AM
americanbankingnews.com logoWest Pharmaceutical Services Inc. (WST) Expected to Post Quarterly Sales of $381.5 Million
www.americanbankingnews.com - April 16 at 9:14 AM
americanbankingnews.com logoSomewhat Positive News Coverage Likely to Impact West Pharmaceutical Services (WST) Share Price
www.americanbankingnews.com - April 14 at 12:26 PM
americanbankingnews.com logoZacks: Brokerages Anticipate West Pharmaceutical Services Inc. (WST) to Announce $0.55 EPS
www.americanbankingnews.com - April 14 at 9:28 AM
finance.yahoo.com logoWest to Host First-Quarter 2017 Conference Call
finance.yahoo.com - April 13 at 8:47 AM
finance.yahoo.com logoETFs with exposure to West Pharmaceutical Services, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 6:36 PM
americanbankingnews.com logoWest Pharmaceutical Services Inc. (WST) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 4 at 3:09 PM
americanbankingnews.com logoBrokerages Anticipate West Pharmaceutical Services Inc. (WST) to Post $0.55 Earnings Per Share
www.americanbankingnews.com - March 30 at 12:11 PM
americanbankingnews.com logoWest Pharmaceutical Services Inc. (WST) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 29 at 8:47 AM
americanbankingnews.com logoWest Pharmaceutical Services Inc. (WST) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 23 at 11:17 AM
nasdaq.com logoWest Pharmaceutical Services (WST) Shares Cross Below 200 DMA
www.nasdaq.com - March 23 at 8:35 AM
seekingalpha.com logoThe Expectations For West Pharmaceutical Look Hard To Meet
seekingalpha.com - March 17 at 3:22 PM
finance.yahoo.com logoWEST PHARMACEUTICAL SERVICES INC Financials
finance.yahoo.com - March 4 at 4:34 AM
biz.yahoo.com logoWEST PHARMACEUTICAL SERVICES INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 28 at 8:28 PM
prnewswire.com logoWest Announces Fourth-Quarter and Full-Year 2016 Results and Announces Quarterly Dividend - PR Newswire (press release)
www.prnewswire.com - February 18 at 7:39 PM
biz.yahoo.com logoWest Pharmaceutical Services Inc Earnings Call (Q4 2016)
biz.yahoo.com - February 17 at 5:15 PM
seekingalpha.com logoWest Pharmaceutical Services Inc. 2016 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 17 at 5:15 PM
us.rd.yahoo.com logoWest Announces Fourth-Quarter and Full-Year 2016 Results and Announces Quarterly Dividend
us.rd.yahoo.com - February 17 at 5:15 PM

Social

Chart

West Pharmaceutical Services (WST) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff